Buerkley Rose

400 total citations
7 papers, 120 citations indexed

About

Buerkley Rose is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Buerkley Rose has authored 7 papers receiving a total of 120 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Biotechnology. Recurrent topics in Buerkley Rose's work include Occupational and environmental lung diseases (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Research and Treatments (3 papers). Buerkley Rose is often cited by papers focused on Occupational and environmental lung diseases (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Research and Treatments (3 papers). Buerkley Rose collaborates with scholars based in United States and Denmark. Buerkley Rose's co-authors include Hedy L. Kindler, Christopher M. Straus, Tanguy Y. Seiwert, Theodore Karrison, Yi‐Hung Carol Tan, Ami V. Desai, Robert M. Sargis, William F. Sensakovic, Alexandra Cunliffe and Aliya N. Husain and has published in prestigious journals such as Journal of Clinical Oncology, European Radiology and Journal of Thoracic Oncology.

In The Last Decade

Buerkley Rose

7 papers receiving 118 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Buerkley Rose United States	5	113	36	14	8	7	7	120
Catherine Ligeza‐Poisson France	7	90 0.8×	45 1.3×	18 1.3×	4 0.5×	4 0.6×	8	125
Judith Bushong United States	6	81 0.7×	77 2.1×	3 0.2×	10 1.3×	9 1.3×	11	94
Benjamin Wadowski United States	5	51 0.5×	11 0.3×	8 0.6×	11 1.4×	2 0.3×	10	69
Sean Dulloo United Kingdom	3	47 0.4×	16 0.4×	8 0.6×	4 0.5×	2 0.3×	11	59
Thierry Chatellier France	5	18 0.2×	18 0.5×	4 0.3×	16 2.0×	14 2.0×	8	50
Anders Bugge Norway	5	56 0.5×	21 0.6×		16 2.0×	11 1.6×	9	68
M Desio Italy	5	80 0.7×	29 0.8×	5 0.4×	62 7.8×	7 1.0×	6	139
Kunal Dalal United States	3	46 0.4×	37 1.0×		8 1.0×	5 0.7×	13	61
Emilio Ansótegui Barrera Spain	6	55 0.5×	17 0.5×		24 3.0×	9 1.3×	11	73
Taisuke Isono Japan	4	42 0.4×	46 1.3×	1 0.1×	3 0.4×	4 0.6×	14	68

Countries citing papers authored by Buerkley Rose

Since Specialization

Citations

This map shows the geographic impact of Buerkley Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Buerkley Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Buerkley Rose more than expected).

Fields of papers citing papers by Buerkley Rose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Buerkley Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Buerkley Rose. The network helps show where Buerkley Rose may publish in the future.

Co-authorship network of co-authors of Buerkley Rose

This figure shows the co-authorship network connecting the top 25 collaborators of Buerkley Rose. A scholar is included among the top collaborators of Buerkley Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Buerkley Rose. Buerkley Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Desai, Ami V., Theodore Karrison, Buerkley Rose, et al.. (2018). OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis. Journal of Thoracic Oncology. 13(10). S339–S339. 45 indexed citations

2.

Labby, Zacariah E., Christopher M. Straus, William F. Sensakovic, et al.. (2018). Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. European Radiology. 29(2). 682–688. 10 indexed citations

3.

Panou, Vasiliki, Caroline Weipert, Aliya N. Husain, et al.. (2018). Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma.. Journal of Clinical Oncology. 36(15_suppl). 8564–8564. 14 indexed citations

4.

Karrison, Theodore, Buerkley Rose, Christopher M. Straus, et al.. (2018). Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).. Journal of Clinical Oncology. 36(15_suppl). 8565–8565. 21 indexed citations

5.

Kindler, Hedy L., Mark Ferguson, Buerkley Rose, et al.. (2017). P2.06-029 Pilot Window-Of-Opportunity Study of Pembrolizumab in Patients with Resectable Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology. 12(1). S1089–S1089. 2 indexed citations

6.

Kindler, Hedy L., Theodore Karrison, Yi‐Hung Carol Tan, et al.. (2017). OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis. Journal of Thoracic Oncology. 12(1). S293–S294. 24 indexed citations

7.

Kindler, Hedy L., Theodore Karrison, Buerkley Rose, et al.. (2017). Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial.. Journal of Clinical Oncology. 35(15_suppl). 8557–8557. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact